Literature DB >> 2566018

Vigabatrin in GABA metabolism disorders.

J Jaeken, P Casaer, P de Cock, B Francois.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2566018     DOI： 10.1016/s0140-6736(89)92466-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

Review 1.  Thirty years beyond discovery--clinical trials in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism.

Authors:  Kara R Vogel; Phillip L Pearl; William H Theodore; Robert C McCarter; Cornelis Jakobs; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2012-06-28       Impact factor: 4.982

Review 2.  Review: Normal and abnormal central nervous system GABA metabolism in childhood.

Authors:  J Jaeken; P Casaer; K D Haegele; P J Schechter
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

3.  Further evaluation of Vigabatrin therapy in 4-hydroxybutyric aciduria.

Authors:  C Jakobs; T Michael; E Jaeger; J Jaeken; K M Gibson
Journal:  Eur J Pediatr       Date:  1992-06       Impact factor: 3.183

4.  Efficacy of vigabatrin intervention in a mild phenotypic expression of succinic semialdehyde dehydrogenase deficiency.

Authors:  M Casarano; M G Alessandrì; G S Salomons; E Moretti; C Jakobs; K M Gibson; G Cioni; R Battini
Journal:  JIMD Rep       Date:  2011-09-06

5.  4-Hydroxybutyric aciduria: clinical findings and vigabatrin therapy.

Authors:  G Uziel; P Bardelli; C Pantaleoni; M Rimoldi; M Savoiardo
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

6.  Vigabatrin therapy in six patients with succinic semialdehyde dehydrogenase deficiency.

Authors:  K M Gibson; C Jakobs; H Ogier; L Hagenfeldt; K E Eeg-Olofsson; O Eeg-Olofsson; F Aksu; H P Weber; E Rossier; B Vollmer
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

7.  Seizures in a boy with succinic semialdehyde dehydrogenase deficiency treated with vigabatrin (gamma-vinyl-GABA).

Authors:  D Matern; W Lehnert; K M Gibson; R Korinthenberg
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

Review 8.  A risk-benefit assessment of vigabatrin in the treatment of neurological disorders.

Authors:  J Srinivasan; A Richens
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.